Back

Semaglutide for the treatment of resistant hypertension

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Secondary and resistant hypertension Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Cormac Kennedy

Trinity College Dublin, Dublin (Ireland)

8 More presentations in this session

Presentation thumbnail
Prediction of outcome in malignant hypertension patients using machine learning: a report from the West Birmingham malignant hypertension registry
Doctor A. Argyris (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Ten-year outcomes in patients with hypertension and primary hyperaldosteronism undergoing surgical adrenalectomy versus medical therapy: data from the multinational collaborative network TriNetX
Doctor R. Belo Nunes (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
The effect of spironolactone versus eplerenone on blood pressure targets in resistant hypertension patients.
Mrs L. Mishchenko (Kyiv, UA)
Abstract Slides Video
Presentation thumbnail
Cerebral damage after malignant hypertensive crisis: cerebral MRI follow-up data
Doctor J. Liegey (Bordeaux, FR)
Abstract Slides Video
Presentation thumbnail
Impaired systemic microvascular function in patients with resistant arterial hypertension and microalbuminuria: an observational study
Doctor E. Tibirica (Rio de Janeiro, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Secondary and resistant hypertension

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
The expanding role of semaglutide in cardiovascular disease and its the effect on blood pressure
thumbnail
Congress Presentation
Survodutide, a glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist, improves cardiometabolic parameters in adults with obesity: analysis of a placebo-controlled, randomised phase 2 trial
thumbnail
Congress Presentation
A dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist increases blood pressure in stroke-prone spontaneous hypertensive rats

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources